Stock listing
GPW:MAB Mabion SA Akcje
Home listing (GPW) of Mabion SA
Follow Mabion SA into a list and get an email when it puts out news.
Share price · GPW:MAB
8.90 PLN -0.54 (-5.7%)
Close on Nov 20, 2026
- Day range
- 8.88 – 9.38 PLNNov 20, 2026
- Volume
- 77,657 sharesNov 20, 2026
- Market cap
- 143.8M PLNAt the close on Nov 20, 2026 · price × 16.16M shares outstanding
- 52-week range
- 6.70 – 11.22 PLNLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 537,338 PLNMedian day 21,207 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| GPW:MAB · Home | 8.90 PLN | -0.54 (-5.7%) | 77,657 | 9.22 | 9.38 | 8.88 | 9.44 | Close on Nov 20, 2026 |
| Frankfurt:272 | €2.015 EUR | -0.02 (-1.0%) | — | €2.015 | €2.015 | €2.015 | €2.035 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · GPW:MAB · PLN, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 8.90 | -0.54 | -5.7% | 9.22 | 9.38 | 8.88 | 77,657 | |
| 9.44 | +0.05 | +0.5% | 9.40 | 9.64 | 9.20 | 60,813 | |
| 9.39 | -0.93 | -9.0% | 10.48 | 10.48 | 9.37 | 210,282 | |
| 10.32 | +0.20 | +2.0% | 10.38 | 11.12 | 10.04 | 283,017 | |
| 10.12 | +0.02 | +0.2% | 10.40 | 11.22 | 9.94 | 742,698 | |
| 10.10 | +2.26 | +28.8% | 7.88 | 10.12 | 7.88 | 654,100 | |
| 7.84 | +0.12 | +1.6% | 7.80 | 7.98 | 7.73 | 35,221 | |
| 7.72 | 0.00 | 0.0% | 7.68 | 7.88 | 7.68 | 16,029 | |
| 7.72 | -0.08 | -1.0% | 7.75 | 7.89 | 7.71 | 11,864 | |
| 7.80 | 0.00 | 0.0% | 7.90 | 8.04 | 7.80 | 32,637 | |
| 7.80 | +0.09 | +1.2% | 7.80 | 7.90 | 7.71 | 13,238 | |
| 7.71 | -0.19 | -2.4% | 7.90 | 7.90 | 7.70 | 14,290 | |
| 7.90 | 0.00 | 0.0% | 7.95 | 7.96 | 7.87 | 19,867 | |
| 7.90 | -0.02 | -0.3% | 7.99 | 8.05 | 7.85 | 14,069 | |
| 7.92 | -0.04 | -0.5% | 7.96 | 7.96 | 7.86 | 10,034 | |
| 7.96 | -0.01 | -0.1% | 8.00 | 8.04 | 7.83 | 16,644 | |
| 7.97 | -0.03 | -0.4% | 7.92 | 8.07 | 7.86 | 14,906 | |
| 8.00 | -0.03 | -0.4% | 8.10 | 8.17 | 7.90 | 23,487 | |
| 8.03 | -0.29 | -3.5% | 8.23 | 8.37 | 8.03 | 33,841 | |
| 8.32 | +0.12 | +1.5% | 8.19 | 8.48 | 8.13 | 83,725 | |
| 8.20 | +0.14 | +1.7% | 8.14 | 8.34 | 8.01 | 44,607 | |
| 8.06 | +0.06 | +0.8% | 8.14 | 8.36 | 7.94 | 76,312 | |
| 8.00 | -0.07 | -0.9% | 7.82 | 8.09 | 7.82 | 12,176 | |
| 8.07 | 0.00 | 0.0% | 8.00 | 8.10 | 7.91 | 18,775 | |
| 8.07 | +0.10 | +1.3% | 7.90 | 8.20 | 7.85 | 52,191 | |
| 7.97 | +0.07 | +0.9% | 7.83 | 8.02 | 7.83 | 8,909 | |
| 7.90 | -0.08 | -1.0% | 7.98 | 7.98 | 7.83 | 22,967 | |
| 7.98 | -0.02 | -0.2% | 7.90 | 8.06 | 7.88 | 9,229 | |
| 8.00 | +0.24 | +3.1% | 7.76 | 8.10 | 7.75 | 42,198 | |
| 7.76 | -0.06 | -0.8% | 7.89 | 7.90 | 7.75 | 17,579 | |
| 7.82 | +0.02 | +0.3% | 7.89 | 7.90 | 7.64 | 22,767 | |
| 7.80 | -0.27 | -3.3% | 8.16 | 8.17 | 7.80 | 42,382 | |
| 8.07 | +0.22 | +2.8% | 7.69 | 8.10 | 7.69 | 15,863 | |
| 7.85 | +0.05 | +0.6% | 7.80 | 7.90 | 7.64 | 11,294 | |
| 7.80 | -0.06 | -0.8% | 7.86 | 7.96 | 7.72 | 14,248 | |
| 7.86 | +0.16 | +2.1% | 7.83 | 7.98 | 7.70 | 26,017 | |
| 7.70 | 0.00 | 0.0% | 7.77 | 7.83 | 7.70 | 7,676 | |
| 7.70 | -0.15 | -1.9% | 7.82 | 7.84 | 7.69 | 16,969 | |
| 7.85 | +0.07 | +0.9% | 7.78 | 7.91 | 7.75 | 21,249 | |
| 7.78 | -0.06 | -0.8% | 7.85 | 7.87 | 7.75 | 12,628 | |
| 7.84 | +0.06 | +0.8% | 7.75 | 7.99 | 7.75 | 16,636 | |
| 7.78 | -0.02 | -0.3% | 7.89 | 7.89 | 7.71 | 33,453 | |
| 7.80 | +0.19 | +2.5% | 7.63 | 7.90 | 7.63 | 23,083 | |
| 7.61 | -0.23 | -2.9% | 7.93 | 8.04 | 7.61 | 55,791 | |
| 7.84 | -0.03 | -0.4% | 7.79 | 8.00 | 7.79 | 25,277 | |
| 7.87 | -0.04 | -0.5% | 7.94 | 7.94 | 7.71 | 11,134 | |
| 7.91 | -0.09 | -1.1% | 8.06 | 8.06 | 7.85 | 18,972 | |
| 8.00 | +0.37 | +4.8% | 7.79 | 8.12 | 7.63 | 74,056 | |
| 7.63 | -0.18 | -2.3% | 7.81 | 7.97 | 7.60 | 52,750 | |
| 7.81 | -0.10 | -1.3% | 7.91 | 8.01 | 7.60 | 45,442 | |
| 7.91 | -0.13 | -1.6% | 8.03 | 8.08 | 7.91 | 11,825 | |
| 8.04 | -0.05 | -0.6% | 8.14 | 8.18 | 7.94 | 21,207 | |
| 8.09 | +0.24 | +3.1% | 7.85 | 8.15 | 7.80 | 59,892 | |
| 7.85 | +0.13 | +1.7% | 7.80 | 7.91 | 7.71 | 37,752 | |
| 7.72 | +0.04 | +0.5% | 7.70 | 7.84 | 7.68 | 17,910 | |
| 7.68 | -0.01 | -0.1% | 7.69 | 7.77 | 7.68 | 18,590 | |
| 7.69 | -0.13 | -1.7% | 7.75 | 7.80 | 7.69 | 20,969 | |
| 7.82 | +0.02 | +0.3% | 7.84 | 7.88 | 7.75 | 12,549 | |
| 7.80 | -0.05 | -0.6% | 7.89 | 7.89 | 7.73 | 19,266 | |
| 7.85 | -0.03 | -0.4% | 7.95 | 8.04 | 7.71 | 56,855 | |
| 7.88 | +0.16 | +2.1% | 7.79 | 8.47 | 7.71 | 247,262 | |
| 7.72 | -0.12 | -1.5% | 7.80 | 7.84 | 7.72 | 17,097 | |
| 7.84 | 0.00 | 0.0% | 7.84 | 7.89 | 7.80 | 18,872 | |
| 7.84 | 0.00 | 0.0% | 7.86 | 7.86 | 7.70 | 13,943 | |
| 7.84 | +0.20 | +2.6% | 7.80 | 7.91 | 7.65 | 86,990 |
- Ticker
- GPW:MAB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- GPW
- Currency
- PLN
What changed lately
Latest news release · Aug 26, 2026
Oddifact and Mabion Receive FDA Pre-IND Meeting Grant for RTX-NP (MabionCD20) in Immune Thrombocytopenia
Latest deck · Sep 15, 2026
H1 2026 Earnings Presentation
Earnings · 15 slides
Latest news
Oddifact and Mabion Receive FDA Pre-IND Meeting Grant for RTX-NP (MabionCD20) in Immune Thrombocytopenia
Aug 26, 2026
Closed 7.88 (+2.1%) on Aug 26, 2026
Other information to the quarterly report of Mabion S.A. for Q1 2026
May 19, 2026
Closed 7.70 (+0.3%) on May 19, 2026
Interim condensed financial statements for the 3-month period ended 31 March 2026
May 19, 2026
Closed 7.70 (+0.3%) on May 19, 2026
Mabion: Financial statements for the financial year ended 31 December 2025
Apr 29, 2026
Closed 7.20 (-7.3%) on Apr 29, 2026
Presentation of financial results for FY 2025 – Mabion
Apr 28, 2026
Closed 7.77 (-5.5%) on Apr 28, 2026
Mabion: Directors’ Report for the year 2025
Apr 28, 2026
Closed 7.77 (-5.5%) on Apr 28, 2026
Mabion: Condensed interim financial statements as at and for the period of 3 months and 9 months ended 30 September 2025
Dec 4, 2025
Closed 7.02 (-1.7%) on Dec 4, 2025
Presentation of financial results for Q3 2025 – Mabion
Dec 2, 2025
Closed 7.04 (-4.2%) on Dec 2, 2025
Other information to the quarterly report of Mabion S.A. for Q3 2025
Dec 1, 2025
Closed 7.04 (-4.2%) on Dec 2, 2025
Mabion SA on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 10 in the last 12 months · 18 in all · newest Aug 26, 2026 · oldest 2024
- Decks
- 24 decks · latest Sep 15, 2026
Where Mabion SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| GPW:MAB · Home listing · This page | GPW | Poland | PLN |
| gettex:272 | gettex | Germany | EUR |
| LSE:0QGW | LSE | United Kingdom | PLN |
| LS Exchange:A1J13Q | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1J13Q | Lang & Schwarz | Germany | EUR |
| Stuttgart:272 | Stuttgart | Germany | EUR |
| Frankfurt:272 | Frankfurt | Germany | EUR |
| Munich:272 | Munich | Germany | EUR |
Valuation
EV/sales 9.7× against a median of 1.1×: the highest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 170.5M PLN
- P/E
- Loss
- EV/sales
- 9.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 6.0×
- Gross margin
- −71.5%
- Operating margin
- −221.3%
- Net margin
- −321.4%
- Debt to equity
- 1.3×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Mabion SA · GPW:MAB | US$35.40M | US$41.96M | n/a | 9.7× | n/a | 6.0× | −321.4% | 1.3× | n/a |
| Harvard Bioscience, Inc. · NASDAQ:HBIO | US$39.60M | US$71.90M | n/a | 0.8× | 28.4× | 7.8× | −13.2% | 7.3× | 1.34 |
| CytoGen, Inc. · KRX:217330 | US$38.59M | US$31.67M | n/a | 1.6× | n/a | 1.6× | −38.5% | 0.4× | n/a |
| HUMASIS Co., Ltd. · KRX:205470 | US$37.49M | −US$89.15M | n/a | −3.8× | n/a | 0.2× | −49.2% | 0.0× | n/a |
| IXICO PLC · LSE:IXI | US$37.25M | US$35.79M | n/a | 4.2× | n/a | 2.7× | −25.3% | 0.1× | n/a |
| Trajan Group Holdings Ltd · ASX:TRJ | US$34.92M | US$64.94M | n/a | 0.6× | 7.6× | 0.5× | −0.4% | 0.6× | n/a |
| Novacyt SAS · EURONEXT:ALNOV | US$33.86M | US$35.58M | n/a | 0.8× | n/a | 1.4× | −102.4% | 0.6× | n/a |
| Rapid Micro Biosystems, Inc. · NASDAQ:RPID | US$33.56M | US$46.06M | n/a | 1.3× | n/a | 3.8× | −138.2% | 2.2× | 1.41 |
| Abnova Taiwan Corp. · TWSE:4133 | US$32.15M | US$20.35M | 23.6× | 1.9× | 13.4× | 0.8× | 13.0% | 0.0× | n/a |
| Precipio, Inc. · NASDAQ:PRPO | US$31.11M | US$27.88M | n/a | 1.0× | 119× | 2.1× | −4.1% | 0.0× | 1.00 |
| Aligned Genetics, Inc. · KRX:238120 | US$31.02M | US$28.31M | 9.0× | 2.4× | 11.8× | 1.1× | 28.7% | 0.3× | n/a |
| Median of the others | US$34.39M | US$33.62M | 16.3× | 1.1× | 13.4× | 1.5× | −19.2% | 0.3× | 1.34 |
Forecasts
Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.00 PLN · Analysts' mean
- Revenue, year to Dec 2025
- 31.1M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Dorota Owczarek | Director, Qualified Person |
| Paweł Pobiedziński | Business Development Director |
Board
| Director | Role |
|---|---|
| Anna Wieczorek | Director |
| Bartłomiej Czubek | Director |
| Edyta Bartusik-Czubek | Director |
| Ilona Hinz | Director |
| Łukasz Waszak | Director |
| Marta Bednarek | Director |
| PhD Anna Czubatka-Bieńkowska | Director |
| Tomasz Kurpiewski | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | May 25, 2026 · Before open | −1.2% |
| Q2 2025 | Sep 9, 2025 · Before open | +0.9% |
| Q1 2025 | May 27, 2025 · Before open | −1.2% |
| Q3 2024 | Nov 5, 2024 · After close | −0.8% |
| Q2 2024 | Sep 10, 2024 · Before open | −1.7% |
| Q1 2024 | May 14, 2024 · Before open | −3.3% |
| Q3 2023 | Nov 14, 2023 · Before open | +3.1% |
| Q2 2023 | Sep 12, 2023 · Before open | +3.1% |
| Q1 2023 | Apr 22, 2023 · Before open | −2.1% |
| Q3 2022 | Nov 24, 2022 · After close | −6.6% |
All 15 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2022 | Sep 30, 2022 | −0.8% |
| Q1 2022 | May 27, 2022 · Before open | −4.0% |
| Q3 2021 | Nov 29, 2021 · After close | −1.6% |
| Quarter to Jun 30, 2021 | Sep 16, 2021 · Before open | +2.0% |
| Quarter to Mar 31, 2021 | May 20, 2021 · After close | +12.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 15 slides | Sep 15, 2026 |
| Investor Presentation (June 2026) | Investor deck | 29 slides | June 2026 |
| Investor Presentation (May 2026) | Investor deck | 29 slides | May 2026 |
| FY2025 Earnings Presentation | Earnings | 25 slides | Apr 28, 2026 |
| Investor Presentation (January 2026) | Investor deck | 27 slides | January 2026 |
| Q3 2025 Earnings Presentation | Earnings | 24 slides | Dec 2, 2025 |
| Investor Presentation (December 2025) | Investor deck | 27 slides | December 2025 |
| Q1 2024 Earnings Presentation | Earnings | 21 slides | May 14, 2024 |
| FY2023 Earnings Presentation | Earnings | 25 slides | Apr 16, 2024 |
| Investor Presentation (February 2024) | Investor deck | 26 slides | February 2024 |
All 24 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2023 Earnings Presentation | Earnings | 19 slides | Sep 12, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 16 slides | May 23, 2023 |
| FY2022 Earnings Presentation | Earnings | 60 slides | Apr 18, 2023 |
| Q3 2022 Earnings Presentation | Earnings | 22 slides | Nov 25, 2022 |
| Q2 2022 Earnings Presentation | Earnings | 20 slides | Sep 30, 2022 |
| Technical Presentation (November 2021) | Technical | 24 slides | Nov 25, 2021 |
| Corporate Update (October 2021) | Corporate update | 19 slides | October 2021 |
| GPW Innovation Day 2021 | Conference | 20 slides | June 2021 |
| Investor Presentation (March 2021) | Investor deck | 38 slides | March 2021 |
| Corporate Update (October 2020) | Corporate update | 24 slides | Oct 30, 2020 |
| Corporate Update (July 2020) | Corporate update | 16 slides | July 2020 |
| Investor Presentation (November 2019) | Investor deck | 20 slides | Nov 25, 2019 |
| Investor Presentation (May 2018) | Investor deck | 32 slides | May 9, 2018 |
| Konferencja WallStreet 2009 | Conference | 21 slides | Jun 6, 2009 |
Financials
Annual, in PLN
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.8M | 69.0M | 151.7M | 164.0M | 56.9M | 1.59M | 0 | 0 | ||
| Cost of revenue | 33.2M | 27.9M | 37.1M | 98.0M | 21.0M | 9.83M | 466.0K | 797.0K | 971.0K | 758.0K |
| Gross profit | -17.4M | 41.2M | 114.6M | 66.0M | 28.2M | -9.83M | -466.0K | -797.0K | -971.0K | -758.0K |
| Research and development | 75.0K | 902.0K | 6.25M | 15.1M | 13.6M | 35.7M | 40.7M | 44.9M | 43.3M | 44.2M |
| Selling, general and administrative | 33.9M | 41.7M | 40.2M | 28.7M | 11.0M | 7.95M | 3.63M | 3.22M | 7.07M | 3.18M |
| Operating income | -52.8M | -7.57M | 55.1M | 28.2M | -11.0M | -56.4M | -63.3M | -64.6M | -62.4M | -55.5M |
| Depreciation and amortization | 9.09M | 8.70M | 7.20M | 8.98M | 8.85M | 9.83M | 11.1M | 10.7M | 8.04M | 6.94M |
| EBITDA | -43.7M | 1.13M | 62.3M | 37.2M | -2.12M | -46.5M | -52.2M | -54.0M | -54.3M | -48.6M |
| Interest expense | 804.0K | 3.15M | 1.22M | 1.94M | 1.53M | 1.41M | 751.0K | 1.92M | 1.72M | 217.0K |
| Income before tax | -62.6M | -1.65M | 49.9M | 22.0M | -10.3M | -55.8M | -63.7M | -68.9M | -57.9M | -55.8M |
| Income tax | 4.68M | 8.63M | -1.15M | -12.2M | -2.77M | 70.0K | ||||
| Net income | -62.6M | -6.33M | 41.3M | 23.2M | 1.90M | -57.2M | -64.7M | -68.9M | -57.9M | -55.8M |
| Earnings per share, basic | -3.87 | -0.39 | 2.55 | 1.43 | 0.12 | -4.17 | -4.72 | -5.26 | -4.91 | -4.84 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 6.37M | 38.4M | 47.8M | 53.6M | 48.7M | 2.40M | 28.0M | 58.4M | 1.04M | 14.8M |
| Short-term investments | 108.0K | |||||||||
| Receivables | 3.17M | 2.87M | 25.5M | 13.6M | 18.7M | 1.87M | 746.0K | 7.00K | 8.00K | 7.00K |
| Inventory | 1.41M | 2.70M | 7.75M | 10.3M | 8.45M | 6.75M | 8.81M | 10.3M | 7.16M | 4.23M |
| Current assets | 12.8M | 45.9M | 90.5M | 82.2M | 82.4M | 11.8M | 40.3M | 72.2M | 9.97M | 23.0M |
| Property, plant and equipment | 88.7M | 65.3M | 71.7M | 71.7M | 72.3M | 68.1M | ||||
| Total assets | 110.4M | 159.5M | 208.3M | 186.2M | 184.2M | 78.3M | 113.5M | 144.7M | 82.4M | 91.2M |
| Accounts payable | 6.13M | 4.38M | 7.94M | 12.8M | 23.2M | 18.1M | 15.9M | 14.3M | 14.0M | 9.91M |
| Current liabilities | 43.9M | 39.1M | 55.3M | 74.3M | 96.1M | 104.6M | 86.4M | 66.5M | 120.4M | 73.5M |
| Long-term debt | 10.2M | 66.0K | 225.0K | 377.0K | 202.0K | 200.0K | 580.0K | 1.39M | 1.86M | |
| Total debt | 12.7M | 4.61M | 35.8M | 7.28M | 20.4M | 36.7M | 21.9M | 5.64M | 66.0M | 12.7M |
| Total liabilities | 55.1M | 48.0M | 90.5M | 109.7M | 130.9M | 155.7M | 135.1M | 102.6M | 136.6M | 87.5M |
| Shareholders' equity | 48.8M | 111.4M | 117.8M | 76.5M | 53.3M | -77.4M | -21.6M | 42.1M | -54.2M | 3.73M |
| Shares outstanding | 16.2M | 16.2M | 16.2M | 16.2M | 15.6M | 13.7M | 13.7M | 13.1M | 11.8M | 11.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -41.6M | 39.9M | -2.33M | 38.8M | -32.9M | -35.2M | -33.8M | -38.9M | -54.1M | -15.2M |
| Capital spending | -892.0K | -12.3M | -38.0M | -16.7M | -31.6M | -3.36M | -9.21M | -6.85M | -7.03M | -2.49M |
| Free cash flow | -42.5M | 26.3M | -40.3M | 22.1M | -64.5M | -38.6M | -43.0M | -45.8M | -61.2M | -17.7M |
| Cash from investing | -795.0K | -12.3M | -38.0M | -16.1M | -31.3M | -3.00M | -9.16M | -6.77M | -7.11M | -2.49M |
| Cash from financing | 10.3M | -36.9M | 34.5M | -17.8M | 110.5M | 12.7M | 12.5M | 103.1M | 47.5M | 26.5M |
| Share buybacks | 1.00K | -10.3M | 2.35M | |||||||
| Change in cash | -32.1M | -9.37M | -5.82M | 4.93M | 46.3M | -25.6M | -30.4M | 57.4M | -13.8M | 8.75M |
Cap table
Built by 6ix from Mabion SA’s releases
- Common shares
- 16,162,326
- Fully diluted
- 16,162,326
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 16,162,326 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 16,162,326 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anna Wieczorek | Director · Since at least Nov 5, 2026 |
| Bartłomiej Czubek | Director · Since at least Nov 5, 2026 |
| Dorota Owczarek | Director, Qualified Person · Since at least Nov 5, 2026 |
| Edyta Bartusik-Czubek | Director · Since at least Nov 5, 2026 |
| Ilona Hinz | Director · Since at least Nov 5, 2026 |
| Łukasz Waszak | Director · Since at least Nov 5, 2026 |
| Marta Bednarek | Director · Since at least Nov 5, 2026 |
| Paweł Pobiedziński | Business Development Director · Since at least Nov 4, 2026 |
| PhD Anna Czubatka-Bieńkowska | Director · Since at least Nov 5, 2026 |
| Tomasz Kurpiewski | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Mabion SA.